The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasia

The Prostate

Volumn 22, Issue 1, 1993, Pages 31-37

  Guess, H A ^a   Heyse, J F ^a   Gormley, G J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

biometry; prostatic hypertrophy; prostatic neoplasms

Indexed keywords

FINASTERIDE; OXIDOREDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOMETRY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; UNITED STATES;

EID: 0027449946     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.2990220105     Document Type: Article

References (12)

1. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
2. Routine screening for cancer of the prostate
3. The value of serum prostate specific antigen determinations before and after radical prostatectomy
4. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume, and benign hyperplasia
5. Clinical use of prostate specific antigen in patients with prostate cancer
6. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
7. Measurement of prostate‐specific antigen in serum as a screening test for prostate cancer
8. The effect of finasteride in men with benign prostatic hyperplasia
9. Multicenter, randomized, double‐blind, placebo‐controlled study to investigate the effect of finasteride (MK‐906) on Stage D prostate cancer
10. The future of data analysis
11. Longitudinal evaluation of prostate‐specific antigen levels in men with and without prostate disease